Goldman Sachs predicts the anti-obesity market to reach $100 billion by 2030. Terns Pharmaceuticals may be a strong contender with its promising GLP-1 weight-loss pill. However, investors should be cautious due to the competitive market and uncertainties in the biotech industry.